Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.

ABSTRACT:

Introduction

It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcomes from first-line chemoimmunotherapy combinations.

Methods

In this international multicenter study, we evaluated the association between baseline BMI, progression-free survival (PFS) and overall survival (OS) in a cohort of patients with stage IV NSCLC consecutively treated with first-line chemoimmunotherapy combinations. BMI was categorized according to WHO criteria.

Results

Among the 853 included patients, 5.3% were underweight; 46.4% were of normal weight; 33.8% were ove

SUBMITTER: Cortellini A 

PROVIDER: S-EPMC8852707 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature